Phosphoinositide 3-kinase mediated signalling contributes to development of diabetes-induced abnormal vascular reactivity of rat carotid artery

Cell Biochemistry and Function

Volumn 24, Issue 1, 2006, Pages 13-22

  Yousif, Mariam H M ^a   Benter, Ibrahim F ^a   Hares, Nisreen ^a   Canatan, Halit ^a   Akhtar, Saghir ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Carbachol; Carotid artery; Diabetes; LY294002; Norepinephrine; STZ

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOTENSIN II; CARBACHOL; ENDOTHELIN 1; GLUCOSE; HISTAMINE; NORADRENALIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; STREPTOZOCIN; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL REACTIVITY; CAROTID ARTERY; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; GLUCOSE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; STREPTOZOCIN DIABETES; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 4-KINASE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CAROTID ARTERIES; DIABETES MELLITUS, EXPERIMENTAL; HYPERGLYCEMIA; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

ANIMALIA;

EID: 31644443484     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1278     Document Type: Article

References (34)

1. Yamagishi S, Nakamura K, Takeuchi M, Imaizumi T. Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention. Int J Clin Pharmacol Res 2004; 24: 129-134.
2. Gracia MJ, Mcnamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 1974; 23: 105-112.
3. Jarrett RJ. Cardiovascular disease and hypertension in diabetes mellitus. Diabetes Metab Rev 1989; 5: 547-558.
4. Oyama Y, Kawasaki H, Hattori Y, Kanno M. Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol 1986; 132: 75-78.
5. Kamata K, Miyata N, Kasuya Y. Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol 1989; 97: 614-618.
6. 1-adrenoceptor stimulation in the absence and presence of extracellular calcium. J Cardiovasc Pharmacol 1990; 16: 239-248.
7. Mayhan WG, Irvine SD, Sharpe GM. Constrictor response of resistance arterioles during diabetes mellitus. Diabetes Res Clin Pract 1999; 44: 147-156.
8. Makino A, Ohuchi K, Kamata K. Mechanisms underlying the attenuation of endothelium-dependent vasodilation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat. Br J Pharmacol 2000; 13: 549-556.
9. Northcott CA, Poy MN, Najjar SM, Watts SW Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of DOCA-salt hypertensive rats. Circ Res 2002; 91: 360-369.
10. Toker A. Protein kinases as mediators of phosphoinositide 3-kinase signalling. Mol Pharmacol 2000; 57: 652-658.
11. Matsui T, Li L, Wu JC, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 2002; 277: 22896-22901.
12. Zdychova J, Komers R. Emerging role of Akt kinase/protein kinase B signalling in pathophysiology of diabetes and its complications. Physiol Res 2005; 54: 1-16.
13. Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signalling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999; 104: 447-457.
14. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium- dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
15. Senthil D, Choudhury GG, McLaurin C, Kasinath BS. Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int 2003; 64: 468-479.
16. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269: 5241-5248.
17. Yousif MH, Benter IF, Akhtar S. Inhibition of calcium/calmodulin- dependent protein kinase II normalizes diabetes-induced abnormal vascular reactivity in the rat perfused mesenteric vascular bed. Auton Autacoid Pharmacol 2003; 23: 27-33.
18. Yousif MH. Role of protein kinases in mediating diabetes-induced augmented vasoconstriction to endothelin-1 in the renal arteries of STZ-diabetic rats. Cell Biochem Funct 2005; 22: 24-31.
19. Northcott CA, Hayflick JS, Watts SW. PI3-kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats: is p110delta the culprit? Hypertension 2004; 43: 885-890.
20. Yousif MH, Benter IF, Akhtar S. The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton Autacoid Pharmacol 2005; 25: 69-78.
21. Howe CJ, Lahair MM, Maxwell JA, et al. Participation of the CaM-kinases in hydrogen peroxide-induced I-kappa B phosphorylation in human T lymphocytes. J Biol Chem 2002; 277: 30469-30476.
22. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-447.
23. Booth G, Stalker TJ, Lafer AM, Scalia J. Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of PKC in vivo. Diabetes 2002; 51: 1556-1564.
24. Beckman JA, Goldfine AB, Gordon MB, Garett LA, Creager MA. Inhibition of PKC beta prevents impaired endothelium dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002; 90: 5-7.
25. Yerneni KK, Bai W, Khan B, Medford R, Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kB in vascular smooth muscle cells. Diabetes 1999; 48: 855-864.
26. Collins T, Cybulsky M. NF-κB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107: 246-255.
27. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
28. Kobayashi N, Mita SI, Yoshida K, et al. Celiperolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 via NF-κB induced by oxidative stress. Hypertension 2003; 42: 1004-1013.
29. Foncea R, Carvajal C, Almarza C, Leighton F. Endothelial cell oxidative stress and signal transduction. Biol Res 2000; 33: 89-96.
30. Zalba G, Beaumont J, San Jose G, Fortune A, Furtuno MA, Diez J. Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J Physiol Biochem 2000; 56: 57-64.
31. Dorn GW 2nd, Force T. PKCascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115: 527-537.
32. 2+ channels via phosphoinositide 3-kinase. FASEB J 1999; 13: 685-694.
33. 2+ channels. Circ Res 2001; 89: 692-699.
34. Kassab E, Mcfarlane SI, Sowers JR. Vascular complications in diabetes and their prevention. Vasc Med 2001; 6: 249-255.